Research Paper Volume 12, Issue 24 pp 25275—25293

DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications

Figure 7. Evaluating the immunotherapeutic response of LUAD subtypes. The expression of immune checkpoint molecules including (A) TIGIT, (B) ICOS, (C) TIM-3 (HAVCR2), (D) CTLA4, and (E) PD-L1 (CD274) between patients with high and low risk. (F) Stemness index values of patients in high- and low-risk groups. (G) Immunotherapeutic responses of patients with high and low risk. LUAD, lung adenocarcinoma; PD-L1, programmed cell death-ligand 1.